Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK510
- Development stage
- Phase 2
- Lead developer
- Base Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
NK510 is a base-edited, allogeneic natural killer (NK) cell therapy developed by Base Therapeutics. It is derived from human peripheral blood and engineered using the AccuBase cytosine base editor to precisely modify key genes in NK cells. This editing enhances the ability of the cells to overcome tumor immune evasion and specifically target and kill cancer cells. The therapy is designed as an off-the-shelf universal product for solid tumors and hematologic malignancies. Preclinical studies have demonstrated strong anti-tumor activity with high specificity and minimal off-target effects. Clinical trials are ongoing for advanced solid tumors including non-small cell lung cancer (NSCLC), osteosarcoma, soft tissue sarcoma, gastric cancer, among others[2][4][5][6][7][8][9].
- Other names
- base edited natural killer cells NK510
Beyond the preview
Go deeper on NK510.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK510.